{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T08:49:06Z","timestamp":1769158146937,"version":"3.49.0"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2023,8,5]],"date-time":"2023-08-05T00:00:00Z","timestamp":1691193600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,8,5]],"date-time":"2023-08-05T00:00:00Z","timestamp":1691193600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Pain Headache Rep"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1007\/s11916-023-01155-w","type":"journal-article","created":{"date-parts":[[2023,8,5]],"date-time":"2023-08-05T11:01:36Z","timestamp":1691233296000},"page":"571-577","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The Role of Step Therapy in the Treatment of Migraine"],"prefix":"10.1007","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8596-9130","authenticated-orcid":false,"given":"Leon S.","family":"Moskatel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niushen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,8,5]]},"reference":[{"issue":"9995","key":"1155_CR1","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/S0140-6736(15)60692-4","volume":"386","author":"T Vos","year":"2015","unstructured":"Vos T, Barber RM, Bell B, Bertozzi-Villa A, Biryukov S, Bolliger I, Charlson F, Davis A, Degenhardt L, Dicker D, Duan L. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990\u20132013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015;386(9995):743\u2013800.","journal-title":"Lancet"},{"key":"1155_CR2","doi-asserted-by":"crossref","unstructured":"Burch R, Rizzoli P, Loder E. The prevalence and impact of migraine and severe headache in the United States: updated age, sex, and socioeconomic\u2010specific estimates from government health surveys. Headache: J Head Face Pain. 2021;61(1):60\u20138.","DOI":"10.1111\/head.14024"},{"issue":"1","key":"1155_CR3","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.jpain.2016.10.005","volume":"18","author":"AD Raval","year":"2017","unstructured":"Raval AD, Shah A. National trends in direct health care expenditures among US adults with migraine: 2004 to 2013. J Pain. 2017;18(1):96\u2013107.","journal-title":"J Pain"},{"key":"1155_CR4","doi-asserted-by":"crossref","unstructured":"\u2022 Gilligan AM, Foster SA, Sainski-Nguyen A, Sedgley R, Smith D, Morrow P. Direct and indirect costs among United States commercially insured employees with migraine. J Occup Environ Med. 2018;60(12):1120\u20137.\u00a0Assessment of healthcare costs of patients with migraine.","DOI":"10.1097\/JOM.0000000000001450"},{"key":"1155_CR5","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/s10194-007-0369-8","volume":"8","author":"J Devine","year":"2007","unstructured":"Devine J, Hadsall R, Cline R, Schommer J, Virnig B. Effect of daily migraine prevention on health care utilisation in an insured patient population. J Headache Pain. 2007;8:105\u201313.","journal-title":"J Headache Pain"},{"key":"1155_CR6","doi-asserted-by":"publisher","first-page":"727","DOI":"10.2165\/11314380-000000000-00000","volume":"23","author":"MJ Lainez","year":"2009","unstructured":"Lainez MJ. The effect of migraine prophylaxis on migraine-related resource use and productivity. CNS Drugs. 2009;23:727\u201338.","journal-title":"CNS Drugs"},{"issue":"2","key":"1155_CR7","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1185\/03007990802664199","volume":"25","author":"DA Wertz","year":"2009","unstructured":"Wertz DA, Quimbo RM, Yaldo AZ, Rupnow MF. Resource utilization impact of topiramate for migraine prevention in the managed-care setting. Curr Med Res Opin. 2009;25(2):499\u2013503.","journal-title":"Curr Med Res Opin"},{"key":"1155_CR8","doi-asserted-by":"crossref","unstructured":"Borges dos Santos MA, dos Santos Dias LL, Santos Pinto CD, da Silva RM, Osorio-de-Castro CG. Factors influencing pharmaceutical pricing-a scoping review of academic literature in health science. J Pharm Policy Pract. 2019;12:1\u20132.","DOI":"10.1186\/s40545-019-0183-0"},{"key":"1155_CR9","unstructured":"Topiramate Drug Information. UpToDate. (n.d.). \nhttp:\/\/www.uptodate.com\/contents\/topiramate-drug-information?source=mostViewed_widget#F229190.\u00a0Accessed 21 May 2023."},{"key":"1155_CR10","unstructured":"Galcanezumab Drug Information. In: UpToDate. https:\/\/www.uptodate.com\/contents\/galcanezumab-drug-information?source=auto_suggest&selectedTitle=1~1---1~4---galc&search=galcanezumab#F52042925. Accessed 21 May 2023"},{"key":"1155_CR11","unstructured":"Sumatriptan Drug Information. UpToDate. (n.d.-b). \nhttps:\/\/www.uptodate.com\/contents\/sumatriptan-drug-information?sectionName=Adult&topicId=9968&search=sumatriptan&usage_type=panel&anchor=F224280&source=panel_search_result&selectedTitle=1~44&showDrugLabel=true&kp_tab=drug_general&display_rank=1#F224261.\u00a0Accessed 21 May 2023."},{"key":"1155_CR12","unstructured":"Rimegepant Drug Information. UpToDate. (n.d.-b). https:\/\/www.uptodate.com\/contents\/rimegepant-drug-information?source=auto_suggest&selectedTitle=1~2---1~2---rime&search=rimegepant#F54266796.\u00a0Accessed 21 May 2023."},{"issue":"1","key":"1155_CR13","first-page":"38","volume":"73","author":"S Hoffman","year":"2018","unstructured":"Hoffman S. Step therapy. Food Drug Law J. 2018;73(1):38\u201365.","journal-title":"Food Drug Law J"},{"key":"1155_CR14","doi-asserted-by":"crossref","unstructured":"Sedghi T, Gronbeck C, Aiudi DA, Grant-Kels JM. Assessing the ethics of prior authorization denials and step therapy policies in dermatology. J Am Acad Dermatol. 2023.","DOI":"10.1016\/j.jaad.2023.02.018"},{"key":"1155_CR15","doi-asserted-by":"crossref","unstructured":"Silberstein SD, Winner PK, Chmiel JJ. Migraine preventive medication reduces resource utilization. Headache: J Head Face Pain. 2003;43(3):171\u20138.","DOI":"10.1046\/j.1526-4610.2003.03040.x"},{"issue":"2","key":"1155_CR16","first-page":"137","volume":"11","author":"LR Etemad","year":"2005","unstructured":"Etemad LR, Yang W, Globe D, Barlev A, Johnson KA. Costs and utilization of triptan users who receive drug prophylaxis for migraine versus triptan users who do not receive drug prophylaxis. J Manag Care Pharm. 2005;11(2):137\u201344.","journal-title":"J Manag Care Pharm"},{"issue":"14","key":"1155_CR17","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.2146\/ajhp060590","volume":"64","author":"AL Feliu","year":"2007","unstructured":"Feliu AL, Rupnow MF, Blount A, Boccuzzi SJ, Vermilyea J. Resource use associated with topiramate in migraine prophylaxis. Am J Health-Syst pharm. 2007;64(14):1483\u201391.","journal-title":"Am J Health-Syst pharm"},{"key":"1155_CR18","doi-asserted-by":"crossref","unstructured":"Silberstein SD, Feliu AL, Rupnow MF, Blount AC, Boccuzzi SJ. Topiramate in migraine prophylaxis: long\u2010term impact on resource utilization and cost. Headache: J Head Face Pain. 2007;47(4):500\u201310.","DOI":"10.1111\/j.1526-4610.2007.00754.x"},{"key":"1155_CR19","doi-asserted-by":"crossref","unstructured":"\u2022 Foster SA, Hoyt M, Ye W, Mason O, Ford JH. Direct cost and healthcare resource utilization of patients with migraine before treatment initiation with calcitonin gene-related peptide monoclonal antibodies by the number of prior preventive migraine medication classes. Curr Med Res Opin. 2022;38(5):653\u201360.\u00a0Examines underexplored topic of economic effect of medication non-responders.","DOI":"10.1080\/03007995.2021.2003127"},{"issue":"1","key":"1155_CR20","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/s10194-022-01492-y","volume":"23","author":"S Khanal","year":"2022","unstructured":"Khanal S, Underwood M, Naghdi S, Brown A, Duncan C, Matharu M, Mistry H. A systematic review of economic evaluations of pharmacological treatments for adults with chronic migraine. J Headache Pain. 2022;23(1):122.","journal-title":"J Headache Pain"},{"key":"1155_CR21","doi-asserted-by":"crossref","unstructured":"Rothrock JF, Bloudek LM, Houle TT, Andress\u2010Rothrock D, Varon SF. Real\u2010world economic impact of onabotulinumtoxin A in patients with chronic migraine. Headache: J Head Face Pain. 2014;54(10):1565\u201373.","DOI":"10.1111\/head.12456"},{"issue":"4","key":"1155_CR22","first-page":"368","volume":"20","author":"A Messali","year":"2014","unstructured":"Messali A, Owens G, Bloudek L, Kori S, Cole A, Chia J. Health care resource utilization following initiation of a triptan: a retrospective claims analysis. J Manag Care Pharm. 2014;20(4):368\u201375.","journal-title":"J Manag Care Pharm"},{"issue":"7","key":"1155_CR23","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1177\/0333102420915167","volume":"40","author":"SC Marcus","year":"2020","unstructured":"Marcus SC, Shewale AR, Silberstein SD, Lipton RB, Young WB, Viswanathan HN, Doshi JA. Comparison of healthcare resource utilization and costs among patients with migraine with potentially adequate and insufficient triptan response. Cephalalgia. 2020;40(7):639\u201349.","journal-title":"Cephalalgia"},{"key":"1155_CR24","unstructured":"Acute treatments for Migraine & Final policy recommendations - ICER. https:\/\/icer.org\/wp-content\/uploads\/2020\/10\/ICER_Acute-Migraine_Final-Evidence-Report_Policy-Recommendations_022520-1.pdf. Accessed 21 May 2023"},{"issue":"15","key":"1155_CR25","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1212\/WNL.0b013e3181d8fff4","volume":"74","author":"A Wilper","year":"2010","unstructured":"Wilper A, Woolhandler S, Himmelstein D, Nardin R. Impact of insurance status on migraine care in the United States: a population-based study. Neurology. 2010;74(15):1178\u201383.","journal-title":"Neurology"},{"key":"1155_CR26","doi-asserted-by":"crossref","unstructured":"Minen MT, Lindberg K, Langford A, Loder E. Variation in prescription drug coverage for triptans: analysis of insurance formularies. Headache: J Head Face Pain. 2017;57(8):1243\u201351.","DOI":"10.1111\/head.13134"},{"key":"1155_CR27","unstructured":"Wang V, Bieser S, Lowe A, Li M, Yuan H. CGRP antagonist (gepant) vs triptan use profiles in individuals with migraine: a multicenter electronic medical record analysis of patient characteristics and emergency department services utilization (P6\u201312.010)."},{"key":"1155_CR28","doi-asserted-by":"crossref","unstructured":"\u2022 Jackson JL, Cogbill E, Santana-Davila R, Eldredge C, Collier W, Gradall A, Sehgal N, Kuester J. A comparative effectiveness meta-analysis of drugs for the prophylaxis of migraine headache. PloSOne. 2015;10(7):e0130733.\u00a0Older but thorough examination of comparative efficacy of preventive medication.","DOI":"10.1371\/journal.pone.0130733"},{"key":"1155_CR29","doi-asserted-by":"crossref","unstructured":"\u2022 Ehrlich M, Hentschke C, Sieder C, Maier-Peuschel M, Reuter U. Erenumab versus topiramate: post hoc efficacy analysis from the HER-MES study. J Headache Pain. 2022;23(1):1\u20138.\u00a0One of only studies comparing a CGRP mAb with an oral preventive.","DOI":"10.1186\/s10194-022-01511-y"},{"key":"1155_CR30","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1007\/s40263-021-00834-9","volume":"35","author":"LH Overeem","year":"2021","unstructured":"Overeem LH, Raffaelli B, Mecklenburg J, Kelderman T, Neeb L, Reuter U. Indirect comparison of topiramate and monoclonal antibodies against CGRP or its receptor for the prophylaxis of episodic migraine: a systematic review with meta-analysis. CNS Drugs. 2021;35:805\u201320.","journal-title":"CNS Drugs"},{"key":"1155_CR31","doi-asserted-by":"crossref","unstructured":"\u2022\u2022 Frank F, Ulmer H, Sidoroff V, Broessner G. CGRP-antibodies, topiramate and botulinum toxin type A in episodic and chronic migraine: a systematic review and meta-analysis. Cephalalgia. 2021;41(11\u201312):1222\u201339.\u00a0Comparison of CGRP mAbs, onabotA, and an oral preventive.","DOI":"10.1177\/03331024211018137"},{"issue":"7","key":"1155_CR32","doi-asserted-by":"publisher","first-page":"2378","DOI":"10.1111\/ene.14828","volume":"28","author":"A Alpuente","year":"2021","unstructured":"Alpuente A, Gallardo VJ, Caronna E, Torres-Ferr\u00fas M, Pozo-Rosich P. Partial and nonresponders to onabotulinumtoxinA can benefit from anti-CGRP monoclonal antibodies preventive treatment: a real-world evidence study. Euro J Neurol. 2021;28(7):2378\u201382.","journal-title":"Euro J Neurol"},{"key":"1155_CR33","doi-asserted-by":"crossref","unstructured":"Goldstein J, Silberstein SD, Saper JR, Ryan Jr RE, Lipton RB. Acetaminophen, aspirin, and caffeine in combination versus ibuprofen for acute migraine: results from a multicenter, double\u2010blind, randomized, parallel\u2010group, single\u2010dose, placebo\u2010controlled study. Headache: J Head Face Pain. 2006;46(3):444\u201353.","DOI":"10.1111\/j.1526-4610.2006.00376.x"},{"issue":"2","key":"1155_CR34","first-page":"1","volume":"6","author":"S Jafari","year":"2018","unstructured":"Jafari S, Khayyamfar F, Ansari I, Jafari R, Afshinmajd S. Comparison of ibuprofen and AAC (acetaminophen, aspirin, caffeine) for treating acute migraine episodes. J Basic Clin Pathophysiol. 2018;6(2):1\u20136.","journal-title":"J Basic Clin Pathophysiol"},{"key":"1155_CR35","doi-asserted-by":"crossref","unstructured":"Misra UK, Kalita J, Yadav RK. Rizatriptan vs. ibuprofen in migraine: a randomised placebo-controlled trial. J Headache Pain. 2007;8:175\u20139.","DOI":"10.1007\/s10194-007-0386-7"},{"key":"1155_CR36","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1007\/s10194-012-0484-z","volume":"13","author":"LA Pini","year":"2012","unstructured":"Pini LA, Guerzoni S, Cainazzo M, Ciccarese M, Prudenzano MP, Livrea P. Comparison of tolerability and efficacy of a combination of paracetamol+ caffeine and sumatriptan in the treatment of migraine attack: a randomized, double-blind, double-dummy, cross-over study. J Headache Pain. 2012;13:669\u201375.","journal-title":"J Headache Pain"},{"key":"1155_CR37","doi-asserted-by":"crossref","unstructured":"Goldstein J, Silberstein SD, Saper JR, Elkind AH, Smith TR, Gallagher RM, Battikha JP, Hoffman H, Baggish J. Acetaminophen, aspirin, and caffeine versus sumatriptan succinate in the early treatment of migraine: results from the ASSET trial. Headache: J Head Face Pain. 2005;45(8):973\u201382.","DOI":"10.1111\/j.1526-4610.2005.05177.x"},{"issue":"5","key":"1155_CR38","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1111\/j.1468-2982.2003.00690.x","volume":"24","author":"RB Lipton","year":"2004","unstructured":"Lipton RB, Bigal ME, Goadsby PJ. Double-blind clinical trials of oral triptans vs other classes of acute migraine medication\u2014a review. Cephalalgia. 2004;24(5):321\u201332.","journal-title":"Cephalalgia"},{"issue":"1","key":"1155_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s10194-016-0703-0","volume":"17","author":"H Xu","year":"2016","unstructured":"Xu H, Han W, Wang J, Li M. Network meta-analysis of migraine disorder treatment by NSAIDs and triptans. J Headache Pain. 2016;17(1):1\u20138.","journal-title":"J Headache Pain"},{"key":"1155_CR40","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1007\/s00228-019-02748-4","volume":"75","author":"M Hou","year":"2019","unstructured":"Hou M, Liu H, Li Y, Xu L, He Y, Lv Y, Zheng Q, Li L. Efficacy of triptans for the treatment of acute migraines: a quantitative comparison based on the dose-effect and time-course characteristics. Euro J Clin Pharmacol. 2019;75:1369\u201378.","journal-title":"Euro J Clin Pharmacol"},{"key":"1155_CR41","doi-asserted-by":"crossref","unstructured":"\u2022\u2022 Johnston K, Popoff E, Deighton A, Dabirvaziri P, Harris L, Thiry A, Croop R, Coric V, L\u2019Italien G, Moren J. Comparative efficacy and safety of rimegepant, ubrogepant, and lasmiditan for acute treatment of migraine: a network meta-analysis. Expert Rev Pharmacoecon Outcomes Res. 2022;22(1):155\u201366. One of few studies looking at comparative efficacy and tolerability of the gepants and lasmiditan.","DOI":"10.1080\/14737167.2021.1945444"},{"key":"1155_CR42","doi-asserted-by":"crossref","unstructured":"\u2022\u2022 Yang CP, Liang CS, Chang CM, Yang CC, Shih PH, Yau YC, Tang KT, Wang SJ. Comparison of new pharmacologic agents with triptans for treatment of migraine: a systematic review and meta-analysis. JAMA network open. 2021;4(10):e2128544-. Comparison of new and old acute treatments for migraine.","DOI":"10.1001\/jamanetworkopen.2021.28544"},{"issue":"6","key":"1155_CR43","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1177\/0333102414547138","volume":"35","author":"Z Hepp","year":"2015","unstructured":"Hepp Z, Dodick DW, Varon SF, Gillard P, Hansen RN, Devine EB. Adherence to oral migraine-preventive medications among patients with chronic migraine. Cephalalgia. 2015;35(6):478\u201388.","journal-title":"Cephalalgia"},{"issue":"1","key":"1155_CR44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s10194-017-0720-7","volume":"18","author":"A He","year":"2017","unstructured":"He A, Song D, Zhang L, Li C. Unveiling the relative efficacy, safety and tolerability of prophylactic medications for migraine: pairwise and network-meta analysis. J Headache Pain. 2017;18(1):1\u20137.","journal-title":"J Headache Pain"},{"issue":"5","key":"1155_CR45","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1517\/14740338.2015.1014797","volume":"14","author":"L V\u00e9csei","year":"2015","unstructured":"V\u00e9csei L, Majl\u00e1th Z, Szok D, Cs\u00e1ti A, Tajti J. Drug safety and tolerability in prophylactic migraine treatment. Expert Opin Drug Saf. 2015;14(5):667\u201381.","journal-title":"Expert Opin Drug Saf"},{"issue":"2","key":"1155_CR46","first-page":"91","volume":"4","author":"P Kangasniemi","year":"1984","unstructured":"Kangasniemi P, Hedman C. Metoprolol and propranolol in the prophylactic treatment of classical and common migraine. A double-blind study Cephalalgia. 1984;4(2):91\u20136.","journal-title":"A double-blind study Cephalalgia"},{"key":"1155_CR47","doi-asserted-by":"crossref","unstructured":"Couch JR, Amitriptyline Versus Placebo Study Group. Amitriptyline in the prophylactic treatment of migraine and chronic daily headache. Headache: J Head Face Pain. 2011;51(1):33\u201351.","DOI":"10.1111\/j.1526-4610.2010.01800.x"},{"issue":"11","key":"1155_CR48","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1001\/archneur.1979.00500470065013","volume":"36","author":"JR Couch","year":"1979","unstructured":"Couch JR, Hassanein RS. Amitriptyline in migraine prophylaxis. Arch Neurol. 1979;36(11):695\u20139.","journal-title":"Arch Neurol"},{"issue":"1","key":"1155_CR49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s10194-019-0976-1","volume":"20","author":"F Ahmed","year":"2019","unstructured":"Ahmed F, Gaul C, Garc\u00eda-Monc\u00f3 JC, Sommer K, Martelletti P. An open-label prospective study of the real-life use of onabotulinumtoxinA for the treatment of chronic migraine: the REPOSE study. J Headache Pain. 2019;20(1):1\u20134.","journal-title":"J Headache Pain"},{"key":"1155_CR50","doi-asserted-by":"publisher","first-page":"586","DOI":"10.3389\/fneur.2017.00586","volume":"8","author":"S Guerzoni","year":"2017","unstructured":"Guerzoni S, Pellesi L, Baraldi C, Cainazzo MM, Negro A, Martelletti P, Pini LA. Long-term treatment benefits and prolonged efficacy of onabotulinumtoxinA in patients affected by chronic migraine and medication overuse headache over 3 years of therapy. Front Neurol. 2017;8:586.","journal-title":"Front Neurol"},{"issue":"6","key":"1155_CR51","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1111\/ane.13600","volume":"145","author":"AA Argyriou","year":"2022","unstructured":"Argyriou AA, Dermitzakis EV, Vlachos GS, Vikelis M. Long-term adherence, safety, and efficacy of repeated onabotulinumtoxinA over five years in chronic migraine prophylaxis. Acta Neurol Scand. 2022;145(6):676\u201383.","journal-title":"Acta Neurol Scand"},{"issue":"3","key":"1155_CR52","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1007\/s13760-018-0978-9","volume":"118","author":"P Yalinay Dikmen","year":"2018","unstructured":"Yalinay Dikmen P, Kosak S, Ilgaz Aydinlar E, Sagduyu KA. A single-center retrospective study of onabotulinumtoxinA for treatment of 245 chronic migraine patients: survey results of a real-world experience. Acta Neurol Belg. 2018;118(3):475\u201384.","journal-title":"Acta Neurol Belg"},{"key":"1155_CR53","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s10194-021-01335-2","volume":"22","author":"F Vandervorst","year":"2021","unstructured":"Vandervorst F, Van Deun L, Van Dycke A, Paemeleire K, Reuter U, Schoenen J, Versijpt J. CGRP monoclonal antibodies in migraine: an efficacy and tolerability comparison with standard prophylactic drugs. J Headache Pain. 2021;22:1\u20131.","journal-title":"J Headache Pain"},{"issue":"1","key":"1155_CR54","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s10194-022-01413-z","volume":"23","author":"LJ Krasenbaum","year":"2022","unstructured":"Krasenbaum LJ, Pedarla VL, Thompson SF, Tangirala K, Cohen JM, Driessen MT. A real-world study of acute and preventive medication use, adherence, and persistence in patients prescribed fremanezumab in the United States. J Headache Pain. 2022;23(1):54.","journal-title":"J Headache Pain"},{"issue":"5","key":"1155_CR55","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1080\/03007995.2022.2059975","volume":"38","author":"P Pozo-Rosich","year":"2022","unstructured":"Pozo-Rosich P, Detke HC, Wang S, Dole\u017eil D, Li LQ, Aurora SK, Reuter U. Long-term treatment with galcanezumab in patients with chronic migraine: results from the open-label extension of the REGAIN study. Curr Med Res Opin. 2022;38(5):731\u201342.","journal-title":"Curr Med Res Opin"},{"issue":"12","key":"1155_CR56","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1080\/14740338.2021.1942839","volume":"20","author":"A Tinsley","year":"2021","unstructured":"Tinsley A, Rothrock JF. Safety and tolerability of preventive treatment options for chronic migraine. Expert Opin Drug Saf. 2021;20(12):1523\u201333.","journal-title":"Expert Opin Drug Saf"},{"issue":"1","key":"1155_CR57","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12883-018-1193-2","volume":"18","author":"A Camporeale","year":"2018","unstructured":"Camporeale A, Kudrow D, Sides R, Wang S, Van Dycke A, Selzler KJ, Stauffer VL. A phase 3, long-term, open-label safety study of Galcanezumab in patients with migraine. BMC Neurol. 2018;18(1):1\u20132.","journal-title":"BMC Neurol"},{"key":"1155_CR58","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s10194-020-01127-0","volume":"21","author":"G Lambru","year":"2020","unstructured":"Lambru G, Hill B, Murphy M, Tylova I, Andreou AP. A prospective real-world analysis of erenumab in refractory chronic migraine. J Headache Pain. 2020;21:1.","journal-title":"J Headache Pain"},{"key":"1155_CR59","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s10194-020-01102-9","volume":"21","author":"R Ornello","year":"2020","unstructured":"Ornello R, Casalena A, Frattale I, Gabriele A, Affaitati G, Giamberardino MA, Assetta M, Maddestra M, Marzoli F, Viola S, Cerone D. Real-life data on the efficacy and safety of erenumab in the Abruzzo region, central Italy. J Headache Pain. 2020;21:1\u20131.","journal-title":"J Headache Pain"},{"key":"1155_CR60","doi-asserted-by":"crossref","unstructured":"Saely S, Croteau D, Jawidzik L, Brinker A, Kortepeter C. Hypertension: a new safety risk for patients treated with erenumab. Headache: J Head Face Pain. 2021;61(1):202\u20138.","DOI":"10.1111\/head.14051"},{"issue":"14","key":"1155_CR61","doi-asserted-by":"publisher","first-page":"1798","DOI":"10.1177\/0333102419888222","volume":"39","author":"M Ashina","year":"2019","unstructured":"Ashina M, Kudrow D, Reuter U, Dolezil D, Silberstein S, Tepper SJ, Xue F, Picard H, Zhang F, Wang A, Zhou Y. Long-term tolerability and nonvascular safety of erenumab, a novel calcitonin gene-related peptide receptor antagonist for prevention of migraine: a pooled analysis of four placebo-controlled trials with long-term extensions. Cephalalgia. 2019;39(14):1798\u2013808.","journal-title":"Cephalalgia"},{"key":"1155_CR62","doi-asserted-by":"crossref","unstructured":"\u2022\u2022 Ashina M, Goadsby PJ, Reuter U, Silberstein S, Dodick DW, Xue F, Zhang F, Paiva da Silva Lima G, Cheng S, Mikol DD. Long\u2010term efficacy and safety of erenumab in migraine prevention: results from a 5\u2010year, open\u2010label treatment phase of a randomized clinical trial. European journal of neurology. 2021 May;28(5):1716\u201325.\u00a0Longest study to date on efficacy and safety of a CGRP mAb.","DOI":"10.1111\/ene.14715"},{"issue":"10","key":"1155_CR63","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1177\/0333102416660552","volume":"37","author":"K Thorlund","year":"2017","unstructured":"Thorlund K, Toor K, Wu P, Chan K, Druyts E, Ramos E, Bhambri R, Donnet A, Stark R, Goadsby PJ. Comparative tolerability of treatments for acute migraine: a network meta-analysis. Cephalalgia. 2017;37(10):965\u201378.","journal-title":"Cephalalgia"},{"issue":"5","key":"1155_CR64","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1177\/0333102420905307","volume":"40","author":"RB Lipton","year":"2020","unstructured":"Lipton RB, Marcus SC, Shewale AR, Dodick DW, Viswanathan HN, Doshi JA. Acute treatment patterns in patients with migraine newly initiating a triptan. Cephalalgia. 2020;40(5):437\u201347.","journal-title":"Cephalalgia"},{"key":"1155_CR65","doi-asserted-by":"crossref","unstructured":"Yang CP, Liang CS, Chang CM, Yang CC, Shih PH, Yau YC, Tang KT, Wang SJ. Comparison of new pharmacologic agents with triptans for treatment of migraine: a systematic review and meta-analysis. JAMA network open. 2021;4(10):e2128544-.","DOI":"10.1001\/jamanetworkopen.2021.28544"},{"issue":"1","key":"1155_CR66","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1080\/14737167.2021.1945444","volume":"22","author":"K Johnston","year":"2022","unstructured":"Johnston K, Popoff E, Deighton A, Dabirvaziri P, Harris L, Thiry A, Croop R, Coric V, L\u2019Italien G, Moren J. Comparative efficacy and safety of rimegepant, ubrogepant, and lasmiditan for acute treatment of migraine: a network meta-analysis. Expert Rev of Pharmacoecon Outcomes Res. 2022;22(1):155\u201366.","journal-title":"Expert Rev of Pharmacoecon Outcomes Res"}],"container-title":["Current Pain and Headache Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11916-023-01155-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11916-023-01155-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11916-023-01155-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,6]],"date-time":"2023-10-06T12:10:30Z","timestamp":1696594230000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11916-023-01155-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,5]]},"references-count":66,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["1155"],"URL":"https:\/\/doi.org\/10.1007\/s11916-023-01155-w","relation":{},"ISSN":["1531-3433","1534-3081"],"issn-type":[{"value":"1531-3433","type":"print"},{"value":"1534-3081","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,5]]},"assertion":[{"value":"16 July 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Leon Moskatel and Niushen Zhang declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}]}}